Market revenue in 2023 | USD 737.4 million |
Market revenue in 2030 | USD 1,893.3 million |
Growth rate | 14.4% (CAGR from 2023 to 2030) |
Largest segment | Adult stem cells |
Fastest growing segment | Induced Pluripotent Stem Cells |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, Very Small Embryonic Like Stem Cells |
Key market players worldwide | Thermo Fisher Scientific Inc, STEMCELL Technologies, CellGenix, PromoCell GmbH, Takara Bio Inc, Lonza Group Ltd, ATCC, Bio-Techne Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to stem cells market will help companies and investors design strategic landscapes.
Adult stem cells was the largest segment with a revenue share of 83.56% in 2023. Horizon Databook has segmented the Japan stem cells market based on adult stem cells, human embryonic stem cells, induced pluripotent stem cells, very small embryonic like stem cells covering the revenue growth of each sub-segment from 2018 to 2030.
Technological advancements pertaining to stem cell research in the country coupled with well-defined regulatory policies for research on human stem cells in the country can be attributed to the large share of the country.
The number of research on iPS stem cells surged in Japan after 2012, when a biologist received a novel prize for his discovery in stem cells. In 2020, an infant received an induced pluripotent stem cell treatment for a liver disorder.
Similarly, in April 2022, researchers at Osaka University announced the initiation of experimental treatment on four patients with corneal disease. The age of patients ranges from 30 to 70 and are expected to receive transplantation of iPS cells.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan stem cells market , including forecasts for subscribers. This country databook contains high-level insights into Japan stem cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account